Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear. Methods: Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease. Results: LC and sarcopenia were successfully induced by TAA. Serum TNF-α levels were increased in LC rats and correlated with myostatin expression, muscle weight, and myofiber diameter. The expression of intestinal occludin and zona occludens-1 was reduced in LC rats and associated with serum TNF-α levels and sarcopenia. In patients with LS ≥7 kPa or sarcopenia, serum TNF-α levels were significantly increased, which was also confirmed when we raised the LS cutoff to 10 kPa. The L3SMI was inversely correlated with serum TNF-α levels in patients with LS ≥7 kPa. TNF-α was reduced by rifaximin, which might have resulted in reduced expression of muscular MuRF1 and myostatin and improvements in myofiber diameters within muscle tissues. Conclusions: These results suggest that serum TNF-α is associated with LC-related sarcopenia. Rifaximin might be effective in reducing serum TNF-α levels and improving sarcopenia in LC, but these results need to be validated in future studies.
Abstract
Background/Aims: Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear. Methods: Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease. Results: LC and sarcopenia were successfully induced by TAA. Serum TNF-α levels were increased in LC rats and correlated with myostatin expression, muscle weight, and myofiber diameter. The expression of intestinal occludin and zona occludens-1 was reduced in LC rats and associated with serum TNF-α levels and sarcopenia. In patients with LS ≥7 kPa or sarcopenia, serum TNF-α levels were significantly increased, which was also confirmed when we raised the LS cutoff to 10 kPa. The L3SMI was inversely correlated with serum TNF-α levels in patients with LS ≥7 kPa. TNF-α was reduced by rifaximin, which might have resulted in reduced expression of muscular MuRF1 and myostatin and improvements in myofiber diameters within muscle tissues. Conclusions: These results suggest that serum TNF-α is associated with LC-related sarcopenia. Rifaximin might be effective in reducing serum TNF-α levels and improving sarcopenia in LC, but these results need to be validated in future studies.
참고문헌 (40)
- Castaneda C, "Elderly women accommodate to a low-protein diet with losses of body cell mass, muscle function, and immune response", Am J Clin Nutr, 62, pp.30~39 (1995)
- Moller N, "Growth hormone and protein metabolism", Clin Nutr, 28, pp.597~603 (2009)
- Fong Y, "Cachectin", TNF or IL-1 alpha induces cachexia with redistribution of body proteins, 1989, ~
- Kanghyug Choi, "The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(4), pp.492~505 (2020), 대한간학회[DOI]
- Sooyeon Oh, "Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(4), pp.476~479 (2020), 대한간학회
- Rantanen T, "Handgrip strength and cause-specific and total mortality in older disabled women : exploring the mechanism", J Am Geriatr Soc, 51, pp.636~641 (2003)
- Kim G, "Prognostic value of sarcopenia in patients with liver cirrhosis : a systematic review and meta-analysis", PLoS One, 12, pp.e0186990~ (2017)
- Ebadi M, "Sarcopenia in cirrhosis : from pathogenesis to interventions", J Gastroenterol, 54, pp.845~859 (2019)
- Jimin Han, "Prognostic implications of trunk muscle mass in liver cirrhosis", Clinical and Molecular Hepatology, 24(3), pp.297~298 (2018), 대한간학회
- Dae Hoe Gu, "Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis", Clinical and Molecular Hepatology, 24(3), pp.319~330 (2018), 대한간학회
- Durand F, "Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography", J Hepatol, 60, pp.1151~1157 (2014)
- Montano-Loza AJ, "Inclusion of sarcopenia within MELD(MELDsarcopenia)and the prediction of mortality in patients with cirrhosis", Clin Transl Gastroenterol, 6, pp.e102~ (2015)
- Kim HY, "Sarcopenia in the prognosis of cirrhosis : going beyond the MELD score", World J Gastroenterol, 21, pp.7637~7647 (2015)
- Ankur Jindal, "Sarcopenia: Ammonia metabolism and hepatic encephalopathy", Clinical and Molecular Hepatology, 25(3), pp.270~279 (2019), 대한간학회
- Davuluri G, "Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress", J Physiol, 594, pp.7341~7360 (2016)
- Qiu J, "Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism", Proc Natl Acad Sci U S A, 110, pp.18162~18167 (2013)
- Kumar A, "Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis", Hepatology, 65, pp.2045~2058 (2017)
- Tilg H, "Serum levels of cytokines in chronic liver diseases", Gastroenterology, 103, pp.264~274 (1992)
- Vrekoussis T, "Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ : an RGB-based model", Anticancer Res, 29, pp.4995~4998 (2009)
- 장보현, "Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases", Journal of Korean Medical Science, 31(12), pp.1943~1948 (2016), 대한의학회
- Nudo CG, "Correlation of laparoscopic liver biopsy to elasticity measurements(FibroScan)in patients with chronic liver disease", Gastroenterol Hepatol(N Y), 4, pp.862~870 (2008)
- Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
- Lee H, "Natural killer cell function tests by flowcytometry-based cytotoxicity and IFN-γ production for the diagnosis of adult hemophagocytic lymphohistiocytosis", Int J Mol Sci, 20, pp.5413~ (2019)
- Kang SH, "Impact of sarcopenia on prognostic value of cirrhosis : going beyond the hepatic venous pressure gradient and MELD score", J Cachexia Sarcopenia Muscle, 9, pp.860~870 (2018)
- Kovacheva EL, "Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways", Endocrinology, 151, pp.628~638 (2010)
- Song HL, "The roles of tumor necrosis factor-alpha in colon tight junction protein expression and intestinal mucosa structure in a mouse model of acute liver failure", BMC Gastroenterol, 9, pp.70~ (2009)
- Leppkes M, "Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation", Int Immunol, 26, pp.509~515 (2014)
- Lee B, "Tight junction in the intestinal epithelium : its association with diseases and regulation by phytochemicals", J Immunol Res, 2018, pp.2645465~ (2018)
- Ponziani FR, "Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications", World J Gastroenterol, 21, pp.12322~12333 (2015)
- Kalambokis GN, "Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites", Clin Gastroenterol Hepatol, 10, pp.815~818 (2012)
- Merli M, "MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis", Liver Int, 33, pp.714~721 (2013)
- Li H, "Nuclear factor-kappa B signaling in skeletal muscle atrophy", J Mol Med(Berl), 86, pp.1113~1126 (2008)
- Ewaschuk J, "Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis", Hepatology, 46, pp.841~850 (2007)
- Ono Y, "Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α", PLoS One, 12, pp.e0182040~ (2017)
- Shayto RH, "Use of rifaximin in gastrointestinal and liver diseases", World J Gastroenterol, 22, pp.6638~6651 (2016)
- Davuluri G, "Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis", J Hepatol, 65, pp.929~937 (2016)
- Tsien C, "Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis", Hepatology, 61, pp.2018~2029 (2015)
- DuPont HL, "Biologic properties and clinical uses of rifaximin", Expert Opin Pharmacother, 12, pp.293~302 (2011)
- Hou Q, "Berberine improves intestinal epithelial tight junctions by upregulating A20expression in IBS-D mice", Biomed Pharmacother, 118, pp.109206~ (2019)
- Xu D, "Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats", Gastroenterology, 146, pp.484~496 (2014)